AU2009352490B2 - 1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands - Google Patents

1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands Download PDF

Info

Publication number
AU2009352490B2
AU2009352490B2 AU2009352490A AU2009352490A AU2009352490B2 AU 2009352490 B2 AU2009352490 B2 AU 2009352490B2 AU 2009352490 A AU2009352490 A AU 2009352490A AU 2009352490 A AU2009352490 A AU 2009352490A AU 2009352490 B2 AU2009352490 B2 AU 2009352490B2
Authority
AU
Australia
Prior art keywords
hydroxy
oxo
compound
carboxamide
dihydroquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009352490A
Other languages
English (en)
Other versions
AU2009352490A1 (en
Inventor
Ishtiyaque Ahmad
Gopinadh Bhyrapuneni
Venkateswarlu Jasti
Pradeep Jayarajan
Rama Sastri Kambhampati
Nagaraj Vishwottam Kandikere
Abdul Rasheed Mohammed
Ramakrishna Nirogi
Sriramachandra Murthy Patnala
Jyothsna Ravula
Anil Karbhari Shinde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suven Life Sciences Ltd
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of AU2009352490A1 publication Critical patent/AU2009352490A1/en
Application granted granted Critical
Publication of AU2009352490B2 publication Critical patent/AU2009352490B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009352490A 2009-09-14 2009-12-29 1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands Ceased AU2009352490B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2224CH2009 2009-09-14
IN2224/CHE/2009 2009-09-14
PCT/IN2009/000745 WO2011030349A1 (en) 2009-09-14 2009-12-29 L -dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands

Publications (2)

Publication Number Publication Date
AU2009352490A1 AU2009352490A1 (en) 2012-04-19
AU2009352490B2 true AU2009352490B2 (en) 2013-06-20

Family

ID=42126528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009352490A Ceased AU2009352490B2 (en) 2009-09-14 2009-12-29 1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands

Country Status (17)

Country Link
US (1) US8598204B2 (ko)
EP (1) EP2507225B1 (ko)
JP (1) JP5540099B2 (ko)
KR (1) KR101386354B1 (ko)
CN (1) CN102639526B (ko)
AU (1) AU2009352490B2 (ko)
CA (1) CA2771885C (ko)
DK (1) DK2507225T3 (ko)
EA (1) EA020227B1 (ko)
ES (1) ES2578628T3 (ko)
HK (1) HK1173140A1 (ko)
IL (1) IL218525A (ko)
MX (1) MX2012002608A (ko)
NZ (1) NZ598505A (ko)
SG (1) SG178557A1 (ko)
WO (1) WO2011030349A1 (ko)
ZA (1) ZA201201429B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405221B (zh) * 2009-04-24 2015-01-21 日产化学工业株式会社 由二环氨基甲酸酯化合物制备2-氮杂金刚烷化合物的方法
RU2549551C2 (ru) * 2009-06-19 2015-04-27 Эббви Инк. Производные диазагомоадамантана и способы их применения
RU2672468C1 (ru) * 2011-12-22 2018-11-15 Конекшис Лайф Сайенсиз Пвт. Лтд. Производные аза-адамантанов и их применение
RU2557249C1 (ru) * 2014-03-03 2015-07-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный технический университет" Способ получения 1-гидрокси-4-адамантанона
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途
IL297543A (en) 2017-11-30 2022-12-01 Arrakis Therapeutics Inc Nucleic acid-binding photoprobes and their uses
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
CN115677567A (zh) * 2022-11-15 2023-02-03 大唐环境产业集团股份有限公司 一种4-氨基-1-哌啶丙醇的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100236A1 (en) * 2004-11-05 2006-05-11 Theravance, Inc. 5-HT4 receptor agonist compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664794A1 (en) 1992-10-16 1995-08-02 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
JPH07324087A (ja) * 1994-04-04 1995-12-12 Taisho Pharmaceut Co Ltd 複素環化合物
US7405235B2 (en) * 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
RU2404179C2 (ru) 2004-12-22 2010-11-20 Тереванс, Инк. Индазол-карбоксамидные соединения
ATE513827T1 (de) 2005-02-22 2011-07-15 Pfizer Oxyindol-derivate als 5ht4-rezeptor-agonisten
JP4970290B2 (ja) 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
WO2006094063A1 (en) * 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
ATE449092T1 (de) 2005-07-22 2009-12-15 Pfizer Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
US8557994B2 (en) * 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100236A1 (en) * 2004-11-05 2006-05-11 Theravance, Inc. 5-HT4 receptor agonist compounds

Also Published As

Publication number Publication date
ES2578628T3 (es) 2016-07-28
AU2009352490A1 (en) 2012-04-19
KR20120081986A (ko) 2012-07-20
US20120277216A1 (en) 2012-11-01
IL218525A (en) 2014-12-31
JP2013504561A (ja) 2013-02-07
JP5540099B2 (ja) 2014-07-02
SG178557A1 (en) 2012-03-29
MX2012002608A (es) 2012-04-02
HK1173140A1 (en) 2013-05-10
DK2507225T3 (en) 2016-07-04
NZ598505A (en) 2013-01-25
US8598204B2 (en) 2013-12-03
EP2507225A1 (en) 2012-10-10
CN102639526A (zh) 2012-08-15
ZA201201429B (en) 2012-10-31
WO2011030349A1 (en) 2011-03-17
EP2507225B1 (en) 2016-06-01
CA2771885A1 (en) 2011-03-17
EA201270421A1 (ru) 2012-09-28
EA020227B1 (ru) 2014-09-30
CN102639526B (zh) 2014-06-04
CA2771885C (en) 2014-04-08
KR101386354B1 (ko) 2014-04-16
IL218525A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
AU2009352490B2 (en) 1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands
CA2483752C (en) Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US7786305B2 (en) Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
AU2010337837B2 (en) Alpha4beta2 neuronal nicotinic acetylcholine receptor ligands
WO2004041161A2 (en) Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity
EP1701724A2 (en) Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
CA3078164A1 (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
CA2773409C (en) Bicyclic compounds as .alpha.4.beta.2 nicotinic acetylcholine receptor ligands
AU2013382944A1 (en) 5-Amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
AU2009355487C1 (en) Bicyclic compounds as alpha4beta2 nicotinic acetylcholine receptor ligands

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ 1, 2-DIHYDRO-2-OXOQUINOLINE COMPOUNDS AS 5-HT 4 RECEPTOR LIGANDS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired